Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinblastine + nilotinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Vinblastine + nilotinib is an investigational combination therapy evaluated primarily for pediatric, adolescent, and young adult patients with refractory or recurrent low-grade glioma. Vinblastine is a vinca alkaloid chemotherapy agent that inhibits mitosis by binding to tubulin and disrupting microtubule formation, leading to cell cycle arrest at metaphase and subsequent cell death. Nilotinib is a small molecule tyrosine kinase inhibitor that targets BCR-ABL, c-Kit (KIT), platelet-derived growth factor receptors (PDGFRA/PDGFRB), and other kinases involved in tumor growth, angiogenesis, and immunomodulation. The rationale for combining these agents lies in their potential synergistic effects on inhibiting tumor proliferation and angiogenesis through distinct but complementary mechanisms of action. This combination has been studied in phase I/II clinical trials under the name VINILO[1][3][4][6].
- Other names
- VINILO
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)TUBB (Tubulin (alpha and beta subunits))PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on vinblastine + nilotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinblastine + nilotinib.